# VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt

> **NCT00299325** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 254 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Rimonabant
- **DRUG:** Placebo (for Rimonabant)
- **OTHER:** Mild hypocaloric diet

## Key facts

- **NCT ID:** NCT00299325
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299325, "VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00299325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*